Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics' stock (OVID) has experienced significant volatility over the past six months, with a 52-week range between $0.24 and $2.01. In August 2024, the company reported business updates and second-quarter financial results, advancing OV888/GV101 to Phase 2 and pausing OV350 development. In November 2025, Ovid Therapeutics missed analysts' consensus estimates, reporting a loss of $0.17 per share. In December 2025, LifeSci Capital initiated coverage with an "Outperform" recommendation. In January 2026, the stock experienced an 11% decrease, with a price of $1.56 and a market cap of $111 million. The next earnings date is estimated for March 10, 2026.

Information regarding demand seasonality for Ovid Therapeutics' products and services was not found. Demand for its products would likely be driven by patient populations with chronic conditions rather than typical seasonal fluctuations.

Ovid Therapeutics Inc., based in New York, is a biopharmaceutical company focused on developing small molecule medicines for brain disorders caused by excess neural excitability, particularly rare epilepsies and seizure-related neurological disorders. The company's pipeline includes OV329 for treatment-resistant seizures, OV4071 for CNS disorders, OV4041 for anxiety and Rett syndrome, OV888/GV101 for cerebral cavernous malformations, and an interest in soticlestat for Dravet and Lennox-Gastaut syndromes. Previously, Ovid's pipeline included OV101 and OV935.

Ovid Therapeutics Inc. is headquartered in New York, NY, United States, and its sales have been reported in the United States.

Ovid Therapeutics has a news sentiment score of 0.86, similar to the average for Medical companies. MarketBeat tracked 3 news articles in a recent week, consistent with its average weekly coverage. No specific events negatively impacting Ovid Therapeutics' brand reputation were prominently found; coverage focuses on pipeline developments, financial results, and analyst ratings.

Ovid Therapeutics Inc. has a significant portion of its stock held by institutional and retail investors. Institutional owners hold 36,794,204 shares, with major shareholders including Takeda Pharmaceutical Co Ltd and Vanguard Group Inc. Retail investors collectively own the largest share of the company, holding 48% of the ownership. Individual insiders hold 3.07% of the shares, with recent sales by Margaret Alexander (CEO) and Jeffrey Rona (CFO).